Tscan therapeutics reports fourth quarter and full year 2022 financial results and highlights upcoming milestones

Phase 1 umbrella trial for tsc-100 and tsc-101 in hematologic malignancies on track to enroll patients into each of the three study arms and provide a clinical update including safety and biomarker data by mid-year 2023
TCRX Ratings Summary
TCRX Quant Ranking